FiCAT-CAR19/22 leverages cutting-edge gene editing to revolutionize CAR-T cell therapy for B-cell malignancies. By integrating CRISPR precision with transposase efficiency, our platform enables site-specific insertion of large genetic constructs, overcoming the limitations of viral vectors. This next-generation approach enhances safety, stability, and therapeutic durability, reducing antigen escape and improving patient outcomes. With streamlined manufacturing and cost efficiency, FiCAT-CAR19/22 is set to transform personalised medicine, making advanced cell therapies more effective and accessible to patients in need.